We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amneal Pharmaceuticals Holding Co | NYSE:AMRX | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 5.87 | 0 | 01:00:00 |
From May 2022 to May 2024
By Colin Kellaher
Amneal Pharmaceuticals Inc. on Friday said it received U.S. Food and Drug Administration approval for Flynetra, a biosimilar to Amgen Inc.'s cancer drug Neulasta.
The Bridgewater, N.J., pharmaceutical company said the approval is its third this year for biosimilars used in oncology, adding that it expects to launch the three products over the second half of the year, along with a full patient support program.
Biosimilars are near-copies of biologic drugs, such as Neulasta, that are made from living cells and are analogous to generic copies of traditional medicines.
The FDA has already approved several biosimilar competitors to Neulasta, which is used to reduce the incidence of infection associated with febrile neutropenia, a serious side effect of chemotherapy.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 27, 2022 06:34 ET (10:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Amneal Pharmaceuticals Chart |
1 Month Amneal Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
